European Medical SolutionsSTU:AS00 45 PB Ratio is 1.66 as of Jun. 26, 2026, which is 25% below its 10-year median of 2.20. GuruFocus rates STU:AS00 with a GF Score™ of 45/100 and a GF Value™ of €8.10. The stock has 2 warning signs investors should review. Among 1,233 Biotechnology companies, European Medical Solutions ranks better than 66.91% on this metric.
European Medical Solutions stock PB Ratio (=1.73) is close to 3-year low of 1.64.
The historical rank and industry rank for European Medical Solutions's PB Ratio or its related term are showing as below:
STU:AS00'
s PB Ratio Range Over the Past 10 Years
Min: 0.11 Med: 2.2 Max: 5.91
Current: 1.74
During the past 13 years, European Medical Solutions's highest PB Ratio was 5.91. The lowest was 0.11. And the median was 2.20.
STU:AS00's PB Ratio is ranked better than 66.91% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs STU:AS00: 1.74
During the past 12 months, European Medical Solutions's average Book Value Per Share Growth Rate was 16.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of European Medical Solutions was 578.70% per year. The lowest was -76.00% per year. And the median was 4.30% per year.
Back to Basics: PB Ratio
European Medical Solutions (STU:AS00) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
European Medical Solutions PB Ratio Related Terms
European Medical Solutions PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, European Medical Solutions's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
European Medical Solutions PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, European Medical Solutions's PB Ratio distribution charts can be found below:
* The bar in red indicates where European Medical Solutions's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
European Medical Solutions (STU:AS00) has a PB Ratio of 1.66 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on European Medical Solutions and its competitors. This is 25% below median its historical median of 2.20. Over the past decade, European Medical Solutions' PB Ratio has ranged from 0.11 to 5.91. According to the industry distribution chart, European Medical Solutions ranks #408 out of 1233 companies in the Biotechnology industry, placing it in the top 33.1%.
Is European Medical Solutions' PB Ratio too high?
European Medical Solutions' current PB Ratio of 1.66 is 25% below median its 10-year median of 2.20. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 5.91. The Biotechnology industry median PB Ratio is 2.80. European Medical Solutions' value of 1.66 is 40.7% below this industry median. Based on the distribution chart, European Medical Solutions ranks #408 out of 1233 companies in the Biotechnology industry, which is above the industry midpoint. Overall, European Medical Solutions has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does European Medical Solutions' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, European Medical Solutions ranks #408 out of 1233 companies for PB Ratio. This puts European Medical Solutions in the upper half of its industry. The industry median PB Ratio is 2.80. European Medical Solutions' value of 1.66 is 40.7% below this benchmark. Historically, European Medical Solutions' own PB Ratio has ranged from 0.11 to 5.91 over the past decade. While the company's 10-year median is 2.20 vs. the industry median of 2.80, European Medical Solutions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. European Medical Solutions's current PB Ratio of 1.66 is 40.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on European Medical Solutions and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. European Medical Solutions's current PB Ratio is 1.66, which is 25% below median its own 10-year median of 2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Medical Solutions stock overvalued right now?
European Medical Solutions (STU:AS00) has a current PB Ratio of 1.66. The stock's GF Value™ is €8.10, compared to a current price of €4.74 — trading 41.5% below its estimated fair value. The current PB Ratio is 1.66, which is 25% below median its 10-year median of 2.20 and 40.7% below the Biotechnology industry median of 2.80. European Medical Solutions' overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For European Medical Solutions (STU:AS00), the current PB Ratio is 1.66 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is European Medical Solutions (STU:AS00) Overvalued in 2026?
Based on GuruFocus' analysis, European Medical Solutions stock appears to be undervalued.
The current stock price of €4.74 is trading 41.5% below its estimated GF Value™ of €8.10.
Key valuation signals for STU:AS00:
PB Ratio: 1.66 (25% below median its 10-year median of 2.20)
GF Value™: €8.10 vs. price of €4.74 (41.5% below fair value)
Industry Position: 40.7% below the Biotechnology median (#408 of 1233)
No single metric tells the full story. See the STU:AS00 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
45GF Score
Get the complete analysis for STU:AS00
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AS00 has been successfully added to your 
